window.GLOSSARY_DATA = [
  {
    "term": "Beta (β)",
    "full_form": "Market Beta",
    "definition": "Measures how much a stock or portfolio moves relative to the overall market, indicating volatility and market risk.",
    "context": "Used in assessing systematic risk and calculating cost of equity (CAPM).",
    "category": "Finance"
  },
  {
    "term": "CAGR",
    "full_form": "Compound Annual Growth Rate",
    "definition": "The average annualized rate of growth of an investment or market over a specific period.",
    "context": "Commonly used to describe market expansion trends or revenue growth.",
    "category": "Finance"
  },
  {
    "term": "CAPM",
    "full_form": "Capital Asset Pricing Model",
    "definition": "A financial model linking expected return to market risk via beta and the risk-free rate.",
    "context": "Used to estimate required return or cost of equity.",
    "category": "Finance"
  },
  {
    "term": "CGM",
    "full_form": "Continuous Glucose Monitoring",
    "definition": "A wearable sensor system that tracks glucose levels continuously in real time.",
    "context": "Used in diabetes management and digital health.",
    "category": "Healthcare"
  },
  {
    "term": "DCF",
    "full_form": "Discounted Cash Flow",
    "definition": "A valuation method estimating a company’s intrinsic value based on the present value of expected future cash flows.",
    "context": "Used in corporate finance, investing, and valuation modeling.",
    "category": "Finance"
  },
  {
    "term": "DM",
    "full_form": "Developed Markets",
    "definition": "Economies with high income, mature industries, and slower growth rates (e.g., U.S., Japan, Germany).",
    "context": "Benchmark group used for comparing performance with EM regions.",
    "category": "Markets"
  },
  {
    "term": "EBITDA",
    "full_form": "Earnings Before Interest, Taxes, Depreciation, and Amortization",
    "definition": "A measure of operating profitability excluding financing and non-cash items.",
    "context": "Used in valuation ratios like EV/EBITDA and profitability analysis.",
    "category": "Finance"
  },
  {
    "term": "EM",
    "full_form": "Emerging Markets",
    "definition": "Rapidly developing economies with higher growth potential but greater risk (e.g., China, India, Brazil).",
    "context": "Key growth driver for global pharma, MedTech, and investment portfolios.",
    "category": "Markets"
  },
  {
    "term": "EV",
    "full_form": "Enterprise Value",
    "definition": "The total value of a firm’s equity plus debt minus cash.",
    "context": "Used in valuation and acquisition comparisons (e.g., EV/EBITDA).",
    "category": "Finance"
  },
  {
    "term": "GPO",
    "full_form": "Group Purchasing Organization",
    "definition": "An entity that consolidates healthcare provider demand to negotiate better prices from suppliers.",
    "context": "Common in U.S. hospital and pharmaceutical contracting.",
    "category": "Healthcare"
  },
  {
    "term": "HEOR",
    "full_form": "Health Economics and Outcomes Research",
    "definition": "The study of economic and clinical value of healthcare interventions using real-world data.",
    "context": "Supports market access, reimbursement, and value-based care evidence.",
    "category": "Healthcare"
  },
  {
    "term": "High Margin",
    "full_form": "",
    "definition": "Indicates strong profitability per dollar of sales, reflecting pricing power or operational efficiency.",
    "context": "Used to describe companies with strong financial performance.",
    "category": "Finance"
  },
  {
    "term": "MDUFA",
    "full_form": "Medical Device User Fee Amendments",
    "definition": "FDA program where device manufacturers pay user fees to fund faster and more predictable regulatory reviews.",
    "context": "Governs U.S. medical device application funding (510(k), PMA, De Novo).",
    "category": "Regulatory"
  },
  {
    "term": "Operating Margin",
    "full_form": "",
    "definition": "The percentage of revenue remaining after operating costs, showing business efficiency and profitability.",
    "context": "Core metric for comparing operating performance across companies.",
    "category": "Finance"
  },
  {
    "term": "Paradigmatic Shift",
    "full_form": "",
    "definition": "A fundamental transformation in industry logic, assumptions, or operating models.",
    "context": "Describes major systemic change, e.g., fee-for-service → value-based care.",
    "category": "Strategy"
  },
  {
    "term": "PDUFA",
    "full_form": "Prescription Drug User Fee Act",
    "definition": "FDA program allowing pharma and biotech firms to pay user fees to fund and accelerate drug and biologic reviews.",
    "context": "Core U.S. regulatory funding framework for NDAs and BLAs.",
    "category": "Regulatory"
  },
  {
    "term": "RWE",
    "full_form": "Real-World Evidence",
    "definition": "Clinical and utilization data collected from actual medical practice, not controlled trials.",
    "context": "Used in regulatory filings, HEOR, and value-based care justification.",
    "category": "Healthcare"
  },
  {
    "term": "Strong Balance Sheet",
    "full_form": "",
    "definition": "Refers to a company with high liquidity, low debt, and strong asset base, implying financial stability.",
    "context": "Indicates low credit risk and strong capacity to invest or withstand downturns.",
    "category": "Finance"
  },
  {
    "term": "VBC",
    "full_form": "Value-Based Care",
    "definition": "A healthcare delivery model that rewards providers for patient outcomes rather than service quantity.",
    "context": "Drives modern healthcare reform and payer-provider alignment.",
    "category": "Healthcare"
  },
  {
    "term": "VBP (China)",
    "full_form": "Volume-Based Procurement",
    "definition": "A centralized purchasing model where large volume commitments secure steep price discounts.",
    "context": "Used by China and some emerging markets to reduce drug and device costs.",
    "category": "Procurement"
  },
  {
    "term": "VBP (Healthcare)",
    "full_form": "Value-Based Payment / Purchasing",
    "definition": "A reimbursement model linking provider payment to healthcare quality and patient outcomes.",
    "context": "Promotes efficiency, quality improvement, and cost reduction.",
    "category": "Healthcare"
  },
  {
    "term": "WACC",
    "full_form": "Weighted Average Cost of Capital",
    "definition": "The average required return from all capital sources (equity + debt).",
    "context": "Used as the discount rate in DCF and investment evaluations.",
    "category": "Finance"
  }
];